Document is current
Any future updates will be listed below
-
Authors
Szepietowski, Jacek C. https://orcid.org/0000-0003-0766-6342
Kemeny, Lajos https://orcid.org/0000-0002-2119-9501
Mettang, Thomas https://orcid.org/0000-0001-5749-0184
Arenberger, Petr https://orcid.org/0000-0002-4800-5877
-
Funding
Funding for this research was provided by:
Les Laboratories Pierre Fabre
- License Information
-
More Information
Article History
Received: 1 August 2024
Accepted: 26 September 2024
First Online: 18 October 2024
Change Date: 27 October 2024
Change Type: Update
Change Details: Revised version of figure 2 updated.
Declarations
:
: Jacek Szepietowski has served as a consultant and/or advisor for AbbVie, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Sanofi-Genzyme, Trevi, UCB, and Vifor; a speaker for AbbVie, Almirall, Eli Lilly, Janssen-Cilag, LEO Pharma, Novartis, Pfizer, and Sanofi-Genzyme; and an investigator for AbbVie, Almirall, Amgen, AnaptysBio, BMS, Boehringer Ingelheim, Celtrion, Galapagos, Galderma, HELM AG, Incyte, InfraRx, Janssen-Cilag, Kiniksa, LEO Pharma, MedImmune, Menlo Therapeutics, Merck, Novartis, Pfizer, Pierre Fabre, Regeneron, Teva, Trevi, and UCB. Lajos Kemeny and Thomas Mettang have no conflicts of interest to declare. Petr Arenberger has served as a consultant and/or advisor for AbbVie, BMS, LEO Pharma, Novartis, Pfizer, Pierre Fabre, MSD, Sanofi, and UCB; and a speaker for AbbVie, Almirall, BMS, Johnson and Johnson, LEO Pharma, Novartis, MSD, and Pfizer.
: This study was conducted in compliance with the Declaration of Helsinki, International Conference on Harmonisation Good Clinical Practice Guidelines, and applicable local laws. The study protocol was approved in each country by applicable independent ethics committees and competent authorities (Supplementary Table ), and written informed consent was obtained from all participants. This study is registered with ClinicalTrials.gov (NCT01084148) and the European Union Clinical Trials Register (EudraCT 2006-002201-31).
